Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

A two-decade analysis of gastric cancer mortality in the U.S.

Belal Mohamed Hamed, Muzamil Khan, Shree Rath et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16038

e16038 Background: Gastric cancer (GC) is the fifth most common cancer globally and remains a significant public health burden, with approximately one mil...

Impact of stereotactic ablative radiotherapy (SABR) on detection of ctDNA in patients with early-stage lung cancer: Interim findings from the prospective SABR-DETECT trial.

Saurav Verma, Sympascho Young, Thomas Kennedy et al. Jun 01, 2025 pp. 3044-3044 10.1200/jco.2025.43.16_suppl.3044

3044 Background: Stereotactic ablative radiotherapy (SABR) is the preferred curative treatment for inoperable patients with stage I/IIA non–small-cell lun...

Exploring decisional needs of patients considering first line treatment of advanced EGFR+ lung cancer: An interpretive descriptive study.

Rena Seeger, Dawn Stacey, Emi Bossio et al. Jun 01, 2025 pp. 8612-8612 10.1200/jco.2025.43.16_suppl.8612

8612 Background: With expanding treatment options for EGFR+ metastatic non-small cell lung cancer (mNSCLC), shared decision-making is important in alignin...

Study on optimizing serum-based lung cancer diagnosis using a multi-biomarker approach.

Hyejin Sung, Jinsu Lee, Sukki Cho et al. Jun 01, 2025 pp. 8032-8032 10.1200/jco.2025.43.16_suppl.8032

8032 Background: Lung cancer remains the leading cause of cancer-related mortality, largely due to the challenges in early diagnosis. Elevated levels of s...

The evolution of breast cancer genetic testing: Comparative outcomes of NCCN, ASCO, and universal guidelines in 6,000+ patients.

Hikmat Abdel-Razeq, Faris Tamimi, Hira Bani Hani et al. Jun 01, 2025 pp. 10619-10619 10.1200/jco.2025.43.16_suppl.10619

10619 Background: Germline genetic testing for breast cancer has significantly advanced over the past decade. At King Hussein Cancer Center, 6,336 breast...

Immune-related endocrinopathy in cancer patients receiving immune checkpoint inhibitor therapy in the nationwide prospective DIRECT cohort.

Hala Awad, Song Yao, Mostafa Refaat Mohamed et al. Jun 01, 2025 pp. 12132-12132 10.1200/jco.2025.43.16_suppl.12132

12132 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, extending patient survival. However, side effects such as endocri...

Machine learning models to predict skeletal-related events in bone metastasis from advanced cancer.

Hirotaka Miyashita, Ken Aoshima Jun 01, 2025 pp. 12074-12074 10.1200/jco.2025.43.16_suppl.12074

12074 Background: Skeletal-related events (SREs) are detrimental clinical events in bone metastasis from advanced cancer, defined by pathologic fracture,...

Evaluation of large language model (LLM)-based clinical abstraction of electronic health records (EHRs) for non-small cell lung cancer (NSCLC) patients.

Kabir Manghnani, Katie Mo, Kunal Nagpal et al. Jun 01, 2025 pp. 11160-11160 10.1200/jco.2025.43.16_suppl.11160

11160 Background: Abstraction is a critical step for converting clinical data from unstructured EHRs into a structured format suitable for real-world data...

Machine learning–based sequential analysis for optimal selection between IRD and KRD regimen in multiple myeloma patients.

Taemin Park, Sung-Soo Park, Eun Kyoung Chung et al. Jun 01, 2025 pp. 7525-7525 10.1200/jco.2025.43.16_suppl.7525

7525 Background: Multiple myeloma (MM) is hematologic malignancy where personalized treatment strategies are essential to improve outcomes. Proteasome inh...

Exploratory study on the impact of intestinal low-dose radiation on the efficacy and prognosis of immunotherapy in metastatic non-small cell lung cancer.

Baiyang Huang, Kaiyue Wang, Jiarui Zhao et al. Jun 01, 2025 pp. 8571-8571 10.1200/jco.2025.43.16_suppl.8571

8571 Background: Radiotherapy (RT) can be a palliative measure for metastases of metastatic non-small cell lung cancer (mNSCLC). However, RT to abdominope...

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

Pei Dong, Wensu Wei, Yulu Peng et al. Jun 01, 2025 pp. 4526-4526 10.1200/jco.2025.43.16_suppl.4526

4526 Background: Non-clear cell renal cell carcinoma (nccRCC) accounts for approximately 25% of all kidney cancers, however, the effect of systemic chemot...

National trends in mortality of gastric cancer among older adults (70+) from 1990 to 2021 across 204 nations: A global burden of disease study.

Muhammad Shaheer Mannan, Husnain Ahmad, Mian Zahid Jan Kakakhel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16074

e16074 Background: Gastric cancer is a malignant disease characterized by the uncontrolled growth of cells in the stomach lining. It is a global health co...

Early examination of national changes in potentially avoidable hospital visits after chemotherapy, 2018–2022.

Pranathi Pilla, Lesi He, Joshua Liao et al. Jun 01, 2025 pp. 11096-11096 10.1200/jco.2025.43.16_suppl.11096

11096 Background: Medicare tallies potentially avoidable hospital visits after chemotherapy and has been publicly reporting this quality measure since 201...

Systemic therapy for advanced epithelioid sarcoma: A meta-analysis of effectiveness and safety study.

Manaswini Krishnakumar, Maha Zafar, Aswanth Reddy Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23558

e23558 Background: Epithelioid sarcoma (ES) is a rare and aggressive type of soft tissue sarcoma (STS) with limited evidence available on systemic therapi...

Real world efficacy and safety of ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma.

Katherine Ismei Zhou, Robin Nanda Baidya, Chenyu Lin et al. Jun 01, 2025 pp. 4086-4086 10.1200/jco.2025.43.16_suppl.4086

4086 Background: IDH1 mutations occur in 13% of patients with intrahepatic cholangiocarcinoma. Ivosidenib is FDA approved for the treatment of advanced, p...

Clinical outcomes in patients with neuroendocrine tumors and concomitant protein energy malnutrition.

Akshay Ratnani, Elvis Obomanu, Yajur Arya et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24057

e24057 Background: Neuroendocrine tumors are slow-growing tumors commonly found in the gastrointestinal tract. Diagnosis is often delayed as patients pres...

Radiotherapy plus nimotuzumab versus cisplatin in low-risk locoregionally advanced nasopharyngeal carcinoma who had favorable response to induction chemotherapy: A randomised, phase III, non-inferiority trial.

Hai-Qiang Mai, Shan-Shan Guo, Li-Ting Liu et al. Jun 01, 2025 pp. 6078-6078 10.1200/jco.2025.43.16_suppl.6078

6078 Background: Patients with low-risk locoregionally advanced nasopharyngeal carcinoma (LA-NPC) have high survival when treated with radiotherapy (RT) p...

Mortality trends in patients with multiple myeloma and renal failure in the United States (1999–2020): A CDC WONDER database analysis.

Saad Nasir, Munira Moosajee, Muhammad Bilal Abid Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19571

e19571 Background: Renal failure (RF) leads to significant treatment challenges, morbidity, and cancer-related mortality in patients with multiple myeloma...

Therapeutic impact of BET inhibition on immune cell death checkpoints in MPN.

Ciro Roberto Rinaldi, Niloofar Amirian, Anya Megan Squires et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18595

e18595 Background: Myeloproliferative neoplasms (MPNs) are haematological cancers characterized by excessive bone marrow cell growth and have the potentia...

Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study.

Jusheng An, Jing Wang, Chunyan Wang et al. Jun 01, 2025 pp. 5510-5510 10.1200/jco.2025.43.16_suppl.5510

5510 Background: Stage IVb, recurrent or persistent cervical cancer patients have limited treatment options and poor survival prognosis. Additionally, 70-...

Molecular profiling using NGS in lung cancer patients: Revolutionizing targeted therapy and personalized treatment.

Sofia Agelaki, Giannis Socrates Mountzios, Konstantinos Samitas et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20654

e20654 Background: Non-small-cell lung cancer (NSCLC) is the most common histological subtype of lung cancer and the leading cause of cancer-related death...

Diagnostic efficacy of <sup>68</sup> Ga-PSMA-PET/CT scan as a single staging modality in prostate cancer: Evidence from a tertiary healthcare centre.

Dr. Sanjay Kumar Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17130

e17130 Background: To explore whether the new 68 Ga-PSMA-PET/CT (Gallium-68 prostate-specific membrane antigen positron emission t...

A phase 2 clinical trial of preoperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab in resectable locoregionally recurrent head and neck squamous cell carcinoma.

Kartik Sehgal, Vickie Y. Jo, Michael J. Dennis et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps6121

TPS6121 Background: Locoregional recurrence is a major cause of death in squamous cell carcinoma of head &amp; neck (HNSCC) initially treated with curativ...

Association of lymphoma and COVID-19 among hospitalized cancer patients: A population-based cohort study.

Jorge Luis Rodriguez Vazquez, Ahmed Bashir Sukhera, Guy Loic Nguefang Tchoukeu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19090

e19090 Background: Recent data has suggested there might be a link between COVID-19 and Lymphoma more complex than only an immunocompromised state....

Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors.

Harold Nathan C. Tan, Khaoula Ben Haj Frej, Lei Kang et al. Jun 01, 2025 pp. 8111-8111 10.1200/jco.2025.43.16_suppl.8111

8111 Background: Thymic tumors are rare cancers with limited therapeutic options, particularly in refractory cases. Immune checkpoint inhibitors (ICIs) su...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page